Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
ESSA Pharma Inc (EPIX)
NASDAQ:EPIX
Holding EPIX?
Track your performance easily
EPIX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.40 - $11.67
Previous Close$1.6
Volume245.71K
Average Volume (3M)886.24K
Market Cap
$71.02M
Enterprise Value-$55.41M
Total Cash (Recent Filing)$126.76M
Total Debt (Recent Filing)$329.26K
Price to Earnings (P/E)―
Beta2.17
Next Earnings
Feb 06, 2025EPS Estimate
-$0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.64
Shares Outstanding44,388,550
10 Day Avg. Volume302,622
30 Day Avg. Volume886,240
Standard Deviation0.28
R-Squared0.10
Alpha0.00069
Financial Highlights & Ratios
Price to Book (P/B)0.57
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-5.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda1.98
Forecast
1Y Price Target
$1.98Price Target Upside23.75% Upside
Rating ConsensusHold
Number of Analyst Covering5
ESSA Pharma News
PremiumCompany Announcements
ESSA Pharma Inc. Reports Strategic Shift Amid Losses
PremiumCompany Announcements
ESSA Pharma Introduces New Executive Severance Plan
Bulls Say, Bears Say
Bulls Say
Financial FlexibilityEPIX's last reported cash balance of $126.8M offers flexibility to evaluate opportunities.
Oncology Drug DevelopmentThe team's established record in oncology drug development may facilitate discussions around outside development candidates in that category.
Strategic ReviewEPIX is engaging in a strategic review to identify external opportunities to maximize shareholder value, including but not limited to in-licensing external assets and reverse mergers.
Bears Say
Clinical TrialsEPIX announced the discontinuation of masofaniten's randomized Phase II trial in combination with enzalutamide in anti-androgen naive mCPRC following an interim analysis that suggested the trial was unlikely to meet the primary endpoint.
Financial ProjectionsBased on projected YE25 cash of ~$105M, analysts are lowering the price target to $2 from $15.
Strategic DecisionsBoard decided to terminate all trials to conserve cash.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
EPIX FAQ
What was ESSA Pharma Inc’s price range in the past 12 months?
ESSA Pharma Inc lowest stock price was $1.40 and its highest was $11.67 in the past 12 months.
What is ESSA Pharma Inc’s market cap?
Currently, no data Available
When is ESSA Pharma Inc’s upcoming earnings report date?
ESSA Pharma Inc’s upcoming earnings report date is Feb 06, 2025 which is in 46 days.
How were ESSA Pharma Inc’s earnings last quarter?
ESSA Pharma Inc released its earnings results on Dec 17, 2024. The company reported -$0.14 earnings per share for the quarter, beating the consensus estimate of -$0.188 by $0.048.
Is ESSA Pharma Inc overvalued?
According to Wall Street analysts ESSA Pharma Inc’s price is currently Undervalued.
Does ESSA Pharma Inc pay dividends?
ESSA Pharma Inc does not currently pay dividends.
What is ESSA Pharma Inc’s EPS estimate?
ESSA Pharma Inc’s EPS estimate is -$0.18.
How many shares outstanding does ESSA Pharma Inc have?
ESSA Pharma Inc has 44,388,550 shares outstanding.
What happened to ESSA Pharma Inc’s price movement after its last earnings report?
ESSA Pharma Inc reported an EPS of -$0.14 in its last earnings report, beating expectations of -$0.188. Following the earnings report the stock price went up 0.613%.
Which hedge fund is a major shareholder of ESSA Pharma Inc?
Among the largest hedge funds holding ESSA Pharma Inc’s share is EntryPoint Capital, LLC. It holds ESSA Pharma Inc’s shares valued at N/A.
---
ESSA Pharma Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$1.98 (23.75% Upside)
$1.98 (23.75% Upside)
Blogger Sentiment
Bullish
EPIX Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 4.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $12.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.8%
Last 30 Days ▼ 7.4%
Last 30 Days ▼ 7.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-73.77%
12-Months-Change
Fundamentals
Return on Equity
-21.12%
Trailing 12-Months
Asset Growth
-14.09%
Trailing 12-Months
Company Description
ESSA Pharma Inc
ESSA Pharma, Inc. engages in the development of small molecule drugs for prostate cancer. It focuses on producing drugs which selectively block the amino-terminal domain (NTD) of the androgen receptor (AR), potentially overcoming the known AR-dependent resistance mechanisms of castration-resistant prostate cancer (CRPC), and providing CRPC patients with the potential for increased progression-free and overall survival. The company was founded by Marianne D. Sadar and Raymond J. Andersen on January 6, 2009 and is headquartered in Vancouver, Canada.
---
EPIX Stock 12 Month Forecast
Average Price Target
$1.98
▲(23.75% Upside)
Technical Analysis
Annovis Bio
―
Karyopharm Therapeutics
―
Palvella Therapeutics
―
Corvus Pharmaceuticals
―
---